Navigation Links
P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth
Date:10/29/2008

rter were $67.4 million, an increase of 10 percent versus the prior year period. Earnings increased behind the benefit of higher unit volume, cost savings, and favorable green coffee bean market conditions. Results for the quarter also included the benefit of $13 million in reduced overhead costs, primarily as the result of reduced current period overhead allocations from P&G in preparation for the planned separation. These benefits were offset by $17 million in insurance proceeds in the base period related to Hurricane Katrina.

Consistent with Folgers pricing policy, Folgers recently announced a list price decrease across the majority of its product offering in response to declining green coffee bean prices.

THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES

(Amounts in Millions)

Consolidated Cash Flows Information

Three Months Ended

September 30

2008 2007

BEGINNING CASH 3,313 5,354

OPERATING ACTIVITIES

NET EARNINGS 3,348 3,079

DEPRECIATION AND AMORTIZATION 810 752

SHARE BASED COMPENSATION EXPENSE 126 106

DEFERRED INCOME TAXES 247 213

GAIN ON SALE OF BUSINESSES &

FIXED ASSETS (317) (121)

CHANGES IN:

ACCOUNTS RECEIVABLE (725) (595)

INVENTORIES (833) (665)

ACCOUNTS PAYABLE, ACCRUED AND

OTHER LIABILITIES 398 74


'/>"/>

SOURCE The Procter & Gamble Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Cardinal Health Reports First Quarter Results
2. uKarma Reports Progress With International Distribution Agreement for Its Xflowsion DVD Series
3. STAAR Surgical Reports 33% Third Quarter Revenue Growth
4. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
5. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
6. LCA-Vision Reports Third Quarter 2008 Financial Results
7. Universal Health Services, Inc. Reports 2008 Third Quarter Results
8. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
9. Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009
10. WellPoint Reports Third Quarter 2008 Results
11. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)... -- A study released this week showing that a grow...e chronic diseases shines a much-needed spotlight ...o one that focuses on primary and secondary preven...eader in disease prevention. , , (Logo: htt...OGO ) , , The study, conducted by Social &...
(Date:1/8/2009)...Tom Torlakson Introduces AB 89 , , SACRAMENTO, ... Lung Cancer Alliance-California (LCA-CA), hailed ...istrict) for his continued leadership in introduci...esearch. For the third consecutive year, legislat...considered in the California Legislature. , ,...
(Date:1/8/2009)...rtful comments, study suggests , , THUR...stimate how strongly they would react to racist ac...ercent of study participants at York University, i...t with a white person rather than a black one, eve...t the black person when he left the room. , "...
(Date:1/8/2009)...ewswire-FirstCall/ -- Hanger Orthopedic Group, Inc...ghout the fourth quarter of 2008 it acquired Maine...tain Orthotic-Prosthetics Center, Riessen,s Orthop...thotics & Prosthetics, and Orthopedic Rehabili...nt care centers to existing markets in Maine, Loui...
Breaking Medicine News(10 mins):Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:Many Turn Blind Eye to Racism 2Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2
...ission tomography (PET) scan images can successful...ollowing the cognitive behavior therapy in patient... prove that cognitive behavior therapy can bring a...l get long lasting results in patients like those ...
...rence of thyroid cancer may be detectable using a ...bin”(Tg) according to a study published by resear...ancer Center and Arthur G. James Cancer Hospital ...ndings were published June 21 online in the Journa...
...borderline ovarian tumors can still preserve their...of the largest study on women with borderline ovar...ity to have a child by getting only one ovary remo...ind of epithelial ovarian tumors. These tumors hav...
...h can now help the clinicians to predict which wou...d sores, also known as pressure sores or pressure ...n their beds in the hospital or at home without mu...r circulation problems and people with diabetes, w...
Other Medicine News:Health News:Tumour marker for detecting early Recurrence of Thyroid cancer may be soon available 2
(Date:1/8/2009)...ated at the initial dose in an ongoing Phase Ib tr...line after three days , , Conference Call Today...re-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nas...st cohort of an ongoing Phase Ib clinical trial of...ide polymerase inhibitor. ANA598 was very well-to...
(Date:1/7/2009)...eral Products in Development Based On Osteotech,s ... Natural BioRegeneration; FDA Filing Anticipated i... 7 Osteotech, Inc. (Na...biologic products for regenerative healing, announ... trial for its DuraTech(TM) BioRegeneration Matrix...
(Date:1/6/2009)...., Jan. 6 In recent controlled stu... of Memphis , scientists found that the patented i...irst and only proven ingredient to increase levels...ing blood nitrate/nitrate (NOx) in human subjects....bles an increase in blood flow to the skeletal mus...
(Date:1/6/2009)...rance, January 6 , ...ollaboration Until,December 2011 , - Expan...Antibody,Discovery in Ophthalmology , - Re...Allergan,Sublicenses to a Third Party , ...unced a reinforcement,of its existing drug discov...
Breaking Medicine Technology:ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4US Oncology Announces Resignation of Chief Financial Officer 4706 1Talk Therapy Proves Effective for Terminal Cancer Patients 17223 1Talk Therapy Proves Effective for Terminal Cancer Patients 17223 2Masimo to Report First Quarter 2008 Financial Results on April 29 2008 17220 1Masimo to Report First Quarter 2008 Financial Results on April 29 2008 17220 221st Congress of the College of Neuropsychopharmacology 17215 121st Congress of the College of Neuropsychopharmacology 17215 2
...ger, M.D., Ph.D. Contributing Editor Harvard Medic...art failure in African American patients has under...ifferently to the same medication. This concept h...ns, and in many cases is due to individual genetic...ses on these issues, valuable new laboratory tools...
.... Contributing Editor The outcome of many illnesse... units (ICUs) has not improved dramatically over t...ech monitors and sophisticated mechanical and phar...d, critically ill patients requiring intensive car...f death and substantial morbidity. Recently, howe...
Other Medicine Technology:Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy. 2Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy. 3Tight Glycemic Control in the ICU 2Tight Glycemic Control in the ICU 3
...ive base of experience and knowledge in the use of...gous platelets are mixed with calcified thrombin a...ved in coagulation take place. Secreted from the p...in, fibronectin, adenosine diphosphate, thromboxan...
Sony DVD Recorder for recording and playback of DVD video discs to complement DP micro video cameras.
...s a 3 CCD 1/3 inch camera that is ideal for micros...n of 800 TV lines and a S/N ratio of 62dB. It is a...The camera incorporates HAD technology that greatl.... The camera features powerful picture contrast co...
...and VTR's that are specially designed for use in m... radiology and operating theater monitoring. The S...ol via RS-232. Their family of products offer seve...digital or analog recording you are looking for, S...
Medicine Products: